While the obesity drug is clearly the company's crown jewel, it's expected that phase II data for the insomnia program, which will be in later this year, will allow it to move into phase III ...
Comprehensive web portal offering general information on obesity, current research and trials, treatment, prevention and consumer protection against fraudulent treatments.